Clinical Trial Detail

NCT ID NCT03361865
Title Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation
Indications

ureter transitional cell carcinoma

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

Therapies

Epacadostat + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.